EUVIMEDEUVIMED entdecken
MetaanalyseSystematische Übersicht

Quantifying Placebo Effects in Hereditary Ataxia Trials: A Meta‐Analysis of Scale for the Assessment and Rating of Ataxia ( SARA) Score Changes

Emilien Petit iD, Adonis Beaubois-Gandoin, Alexandra Durr, Sophie Tezenas du Montcel iD, Giulia Coarelli iD

Movement Disorders · 2026

DOI: 10.1002/mds.70151 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Movement Disorders, 2026. Verfasst von Emilien Petit und 4 weiteren Autor:innen. Beteiligte Einrichtung: Institut du Cerveau-Paris Brain Institute-ICM, CNRS, Inria, Inserm, AP-HP, Groupe Hospitalier Sorbonne Université, Sorbonne Université, Paris, France. Hauptthemen laut MEDLINE: Clinical Trials as Topic, Friedreich Ataxia, Outcome Assessment, Health Care, Placebo Effect. Die Arbeit nennt 24 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and objectives The Scale for the Assessment and Rating of Ataxia (SARA) is the primary outcome most frequently used in clinical trials involving hereditary ataxia patients. This systematic review and meta‐analysis aimed to quantify changes in SARA scores within placebo arms of these trials to better understand the placebo effect.

Methods

Placebo arm data were collected from clinical trials on hereditary ataxias via PubMed and ClinicalTrials.gov . Heterogeneity was assessed with funnel plots. A random‐effects meta‐analysis was conducted on trials providing variance data. The influence of covariates such as trial duration, continent, intervention type, publication date, and trial result was evaluated.

Results

Thirty‐four trials with placebo arms, including patients with spinocerebellar ataxias and Friedreich's ataxia, were identified. Trial durations ranged from 1 to 52 weeks. Thirty‐seven assessment points were included in the meta‐analysis, revealing substantial heterogeneity ( I 2 = 94%). Placebo response differed significantly by continent, with European trials showing minimal effect (0.01 [−0.35; 0.37]) and Asian trials the largest effect (−0.85 [−1.13; −0.58]). Intervention type also impacted placebo response, with device interventions exhibiting the strongest effect (−0.84 [−1.60; −0.08]). Trial duration showed no statistically significant effect; however, a trend of decreasing placebo effect over time was observed.

Discussion

The analysis indicates a measurable placebo effect on SARA scores. Both intervention type and geographic region significantly influenced the strength of this effect, suggesting roles for patient expectations and cultural factors. Additionally, there was a trend toward reduction of placebo response as trial duration increased. © 2026 International Parkinson and Movement Disorder Society.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Clinical Trials as TopicFriedreich AtaxiaOutcome Assessment, Health CarePlacebo EffectSeverity of Illness IndexSpinocerebellar AtaxiasSpinocerebellar DegenerationsHumans

Stichwörter der Autor:innen

SARAataxiaplacebo response

Autor:innen und Institutionen

  • Institut du Cerveau-Paris Brain Institute-ICM, CNRS, Inria, Inserm, AP-HP, Groupe Hospitalier Sorbonne Université, Sorbonne Université, Paris, France.
  • Genetics Department, University Hospital Pitié-Salpêtrière, AP-HP Sorbonne Université, Paris, France.

ORCID-Profile: Emilien Petit, Sophie Tezenas du Montcel, Giulia Coarelli

Zitieren

APA

Petit, E., Beaubois-Gandoin, A., Durr, A., du Montcel, S. T., & Coarelli, G. (2026). Quantifying Placebo Effects in Hereditary Ataxia Trials: A Meta‐Analysis of Scale for the Assessment and Rating of Ataxia ( SARA) Score Changes. Movement Disorders. https://doi.org/10.1002/mds.70151

Vancouver

Petit E, Beaubois-Gandoin A, Durr A, du Montcel ST, Coarelli G. Quantifying Placebo Effects in Hereditary Ataxia Trials: A Meta‐Analysis of Scale for the Assessment and Rating of Ataxia ( SARA) Score Changes. Movement Disorders. 2026. doi:10.1002/mds.70151

BibTeX
@article{Petit2026,
  author = {Petit, Emilien and Beaubois-Gandoin, Adonis and Durr, Alexandra and du Montcel, Sophie Tezenas and Coarelli, Giulia},
  title = {Quantifying Placebo Effects in Hereditary Ataxia Trials: A Meta‐Analysis of Scale for the Assessment and Rating of Ataxia ( SARA) Score Changes},
  journal = {Movement Disorders},
  year = {2026},
  doi = {10.1002/mds.70151}
}
Kostenlos starten →